Myriad Genetics (MYGN) Competitors $4.47 -0.35 (-7.26%) Closing price 04:00 PM EasternExtended Trading$4.43 -0.04 (-0.89%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MYGN vs. FOLD, BCRX, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, and RGLSShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Its Competitors Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Innoviva MannKind Novavax OPKO Health Geron Regulus Therapeutics Myriad Genetics (NASDAQ:MYGN) and Amicus Therapeutics (NASDAQ:FOLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Does the media prefer MYGN or FOLD? In the previous week, Amicus Therapeutics had 11 more articles in the media than Myriad Genetics. MarketBeat recorded 13 mentions for Amicus Therapeutics and 2 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.49 beat Amicus Therapeutics' score of 1.01 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in MYGN or FOLD? 99.0% of Myriad Genetics shares are held by institutional investors. 2.4% of Myriad Genetics shares are held by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend MYGN or FOLD? Myriad Genetics presently has a consensus price target of $14.38, indicating a potential upside of 221.80%. Amicus Therapeutics has a consensus price target of $16.22, indicating a potential upside of 172.18%. Given Myriad Genetics' higher possible upside, equities research analysts clearly believe Myriad Genetics is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Myriad Genetics 2 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is MYGN or FOLD more profitable? Amicus Therapeutics has a net margin of -5.41% compared to Myriad Genetics' net margin of -12.20%. Amicus Therapeutics' return on equity of 4.67% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Myriad Genetics-12.20% -4.95% -3.39% Amicus Therapeutics -5.41%4.67%1.05% Which has stronger earnings and valuation, MYGN or FOLD? Amicus Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyriad Genetics$837.60M0.49-$127.30M-$1.12-3.99Amicus Therapeutics$528.29M3.47-$56.11M-$0.09-66.22 Which has more volatility & risk, MYGN or FOLD? Myriad Genetics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. SummaryAmicus Therapeutics beats Myriad Genetics on 9 of the 16 factors compared between the two stocks. Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$444.30M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-3.998.2821.0120.09Price / Sales0.49303.17433.8199.01Price / Cash4.8242.5936.1658.27Price / Book0.587.678.125.65Net Income-$127.30M-$55.28M$3.25B$257.91M7 Day Performance-16.29%2.50%0.97%2.09%1 Month Performance-11.83%11.70%7.36%11.13%1 Year Performance-83.20%4.89%31.31%18.40% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics4.5811 of 5 stars$4.47-7.3%$14.38+221.8%-82.2%$444.30M$837.60M-3.992,700News CoveragePositive NewsFOLDAmicus Therapeutics4.1574 of 5 stars$6.05-0.8%$16.22+168.1%-40.7%$1.86B$528.29M-67.21480News CoveragePositive NewsAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.3926 of 5 stars$8.76-2.0%$16.70+90.6%+19.7%$1.83B$450.71M-33.69530Positive NewsAnalyst RevisionCLDXCelldex Therapeutics2.4484 of 5 stars$20.98-4.6%$50.11+138.9%-40.8%$1.39B$7.56M-7.77150Positive NewsDVAXDynavax Technologies4.3821 of 5 stars$10.30+0.3%$24.00+133.0%+0.0%$1.24B$277.25M-19.81350INVAInnoviva4.0829 of 5 stars$18.91-1.6%$55.00+190.9%+13.9%$1.19B$369.84M-18.72100Analyst RevisionGap UpMNKDMannKind2.6384 of 5 stars$3.54-1.7%$10.33+191.9%-32.8%$1.08B$285.50M35.40400News CoverageAnalyst UpgradeInsider TradeAnalyst RevisionNVAXNovavax4.3314 of 5 stars$6.61-2.8%$17.00+157.2%-55.8%$1.07B$682.16M2.491,990OPKOPKO Health4.0156 of 5 stars$1.34-1.5%$2.75+105.2%-2.8%$1.06B$713.10M-19.142,997Positive NewsGERNGeron3.46 of 5 stars$1.37-4.2%$5.06+269.5%-72.9%$872.58M$76.99M-6.5270News CoverageRGLSRegulus Therapeutics1.6649 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830 Related Companies and Tools Related Companies FOLD Alternatives BCRX Alternatives CLDX Alternatives DVAX Alternatives INVA Alternatives MNKD Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives RGLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYGN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYGN Stock Alerts